ReNeuron was on the move on Thursday as private client investors bought the stem cell research group in anticipation of it refiling an application to commence a clinical study for its ReN001 stem cell therapy for strokes.

The US Food and Drug Administration placed the study on hold nine months ago and requested further data, which ReNeuron are due to submit in the next two months with the hope of beginning trials next year.